North America Sickle Cell Disease Market, By Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), By Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Country (U.S., and Canada) is estimated to be valued at US$ 1,036.5 Million in 2023 and is expected to exhibit a CAGR of 16.2% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adopting growth strategies, such as the launch of new products in collaboration, which will drive the North America sickle cell disease market growth. For instance, on June 8, 2023, Vertex Pharmaceuticals Incorporated, a U.S.-based biopharmaceutical company, and CRISPR Therapeutics, a U.S. biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-dependent Beta Thalassemia (TDT).
North America Sickle Cell Disease Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a negative impact on the North America sickle cell disease market. Patients were compelled to stay at home because there were no beds available for treating critical patients who couldn't be treated at home owing to COVID-19.
North America Sickle Cell Disease Market: Key Developments
On July 17, 2023, Scribe Therapeutics Inc., a genetic medicine company unlocking the potential of CRISPR to transform human health, announced an expanded collaboration with Sanofi. Under the agreement, Sanofi received an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of Natural Killer (NK) cell therapies for the treatment of cancer.
Browse 17 Market Data Tables and 24 Figures spread through 136 Pages and in-depth TOC on “North America Sickle Cell Disease Market”- Forecast to 2030, North America Sickle Cell Disease Market, By Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), By Drug Type (Hydroxyurea, L-glutamine, crizanlizumab, pain-relievers, voxelotor, and others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Country (U.S., and Canada).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/north-america-sickle-cell-disease-market-4510
Key Takeaways of the North America Sickle Cell Disease Market:
- The North America sickle cell disease market is expected to exhibit a CAGR of 2% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the North America sickle cell disease market.
- Among disease type, the sickle cell anemia segment is expected to hold a dominant position in the North America sickle cell disease market during the forecast period, and this is attributed to the technological advancements in the field of drug development. For instance, on August 22, 2023, Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of Sickle Cell Disease (SCD).
- Among country, U.S. is expected to be the dominant region in the North America sickle cell disease market owing to the key players focusing on organic strategies to launch new products for pain management. For instance, on August 8, 2023, HPC International, a leading purchased services provider for healthcare, corporations, and academic institutions, partnered with Klein Buendel, Inc., a health communication research and technology firm, to create Pinpoint, the first-of-its-kind sickle cell pain management app, which provides a safe, interactive, and convenient way for patients to learn about, track, assess, and communicate with their doctors about their sickle cell pain.
- The major players operating in the North America sickle cell disease market are Novartis International AG, Bristol-Myers Squibb Company, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., IMARA, Inc., bluebird bio, Inc., CRISPR Therapeutics, Scribe Therapeutics Inc., Fulcrum Therapeutics, Inc., HPC International, Editas Medicine, Inc., Nicox SA, Fera Pharmaceuticals, and Tessera Therapeutics
